Receive The Newest Study Notifications

NYU School of Medicine will lead trials testing CBD treatment for patients with Alcohol Use Disorder and Post-Traumatic Stress Disorder with Alcohol Use Disorder Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production, and...

Cancer Research UK, the world's leading cancer charity, and Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, have today (Thursday) announced a partnership to develop Hummingbird's anti-HER3 antibody drug, HMBD-001, for the treatment...

The prospective, randomized, double-blinded, sham-controlled study is designed to evaluate the safety and preliminary efficacy of IDCT at two dosage levels in subjects with single-level, symptomatic lumbar DDD, a major cause of chronic low back pain Image Courtesy:...

Quantum Leap Healthcare Collaborative (QLHC) joins Merck in acknowledging the promising data from the KEYNOTE-522 trial. Merck recently announced that the Phase 3 KEYNOTE-522 trial met a primary endpoint, demonstrating statistically significant improved rates of...

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the filing of a Phase 2 protocol with the FDA for...

Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovarian cancer in its Phase 1...

Retrotope announced today that it has fully enrolled all patients in the first clinical trial of a possible treatment for infants with the ultra-rare neurodegenerative disease, Infantile Neuroaxonal Dystrophy (INAD).  The U.S. Food and Drug Administration (FDA) has...

DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the first patients have been treated in its...

 Retrotope announced today that it has fully enrolled all patients in the first clinical trial of a possible treatment for infants with the ultra-rare neurodegenerative disease, Infantile Neuroaxonal Dystrophy (INAD).  The U.S. Food and Drug Administration (FDA) has...

Eureka Therapeutics has initiated a phase 1/2 clinical trial of its ET140202 Artemis T-cell therapy for the treatment of liver cancer, according to a press release. The company will evaluate ET140202 in combination with its Artemis antibody T-cell receptor platform...

AstraZeneca and Merck’s LYNPARZA Improved Radiographic Progression Free Survival vs. Standard of Care in Patients Selected for BRCA 1/2 or ATM Mutations Only PARP Inhibitor with Positive Phase 3 Results in Four Different Cancer Types AstraZeneca and Merck (MRK), known...

- Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine - Over 1,600 patients have been enrolled in this Phase 3 preventive treatment of migraine trial with rimegepant and topline data is...

Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) LAUSANNE, Switzerland, Aug. 6, 2019 /PRNewswire/ -- ADC Therapeutics, an oncology drug discovery...

Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen supports opening Phase 2 SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company...

When an existing ClinOne client enabled our MD Referral application to support a global phase II study across the United States, Europe and Australia their results far surpassed everyone’s expectations. The sponsor’s aggressive goal to randomize 400 patients diagnosed...

U.S. FDA submission for children planned for 4Q 2019 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its...

Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced initiation of Phase 1/2 clinical trial of ET140202 ARTEMIS™ T-Cell therapy in liver cancer...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced dosing of the first patient in the SKYLIGHT 1™ Phase 3 pivotal trial for fezolinetant, an investigational oral, non-hormonal compound being studied for the treatment...

Dr. Paul Goodyer, Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, is the principal investigator in the Phase 2 clinical trial On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis...

HCL Technologies (HCL), a leading global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences today announced a collaboration to help life sciences companies execute and scale the next generation of digital...